Liquid biopsy to differentiate types of primary liver cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to develop and validate a non-invasive liquid biopsy that analyzes exosomal microRNAs to differentiate between hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). By utilizing machine learning and bioinformatics, the researchers seek to create a cost-effective and sensitive assay that can provide accurate diagnoses before surgical intervention. The study will involve patients with histologically confirmed diagnoses of either HCC or ICC, who have provided blood samples prior to treatment. This approach addresses the clinical need for a safer diagnostic method compared to traditional invasive tissue sampling.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* A histologically confirmed diagnosis of hepatocellular carcinoma
* A histologically confirmed diagnosis of intrahepatic cholangiocarcinoma
* Received standard diagnostic and staging procedures as per local guidelines
* Availability of at least one blood-derived sample, drawn before receiving any curative-intent treatment

Exclusion Criteria:

* Lack of or inability to provide informed consent
* Synchronous hepatocellular carcinoma and intrahepatic cholangiocarcinoma
* Primary liver cancer other than hepatocellular carcinoma or intrahepatic cholangiocarcinoma
* Secondary liver cancer

Where it's running

• City of Hope Medical Center
  Duarte, California, United States Recruiting
• Graduate School of Medical Sciences, Kyushu University
  Fukuoka, Japan Recruiting
• Graduate School of Medical Sciences, Kumamoto University
  Kumamoto, Japan Recruiting
• Hokkaido University Graduate School of Medicine
  Sapporo, Japan Recruiting
• Tokushima University
  Tokushima, Japan Recruiting

Study contacts

• Principal investigator: Ajay Goel, PhD — City of Hope Medical Center
• Study coordinator: Ajay Goel, PhD
• Email: AJGOEL@COH.ORG
• Phone: 6262183452

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating liver embolization techniques for tumor management

  This study tests different liver embolization methods to see how well they help people with liver tumors live longer and maintain liver function while they continue their usual treatments.

  Recruiting IRCCS San Raffaele · Milan · NCT05714124

• 68Ga-SorB PET/CT imaging for solid tumors

  This study tests a new PET tracer called 68Ga-SorB to see if it can safely and accurately detect tumors in adults with melanoma, liver, lung, breast, pancreatic, ovarian cancer, or cholangiocarcinoma.

  Recruiting Peking University Third Hospital · Beijing, Beijing Municipality · NCT07760012

• Dual-target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer

  This trial tests a ready-to-use CAR-NK cell therapy that targets HER2 and CEACAM5 in adults with unresectable or metastatic biliary tract cancers after standard therapy to see if it can help control the disease.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07641036

• Laryngopharyngeal injuries after breathing tube placement during general anesthesia

  This project sees how often and why people who had a breathing tube during general anesthesia developed hoarseness or other throat problems after non-ear–nose–throat surgery.

  Recruiting Zhejiang University · Hangzhou, Zhejiang and 1 other locations · NCT07359586

• Using contrast-enhanced ultrasound to check Y-90 radioembolization response in liver cancer

  This will test whether contrast-enhanced ultrasound (CEUS) can show treatment response to Y‑90 radioembolization in people with newly diagnosed hepatocellular carcinoma who are scheduled for TARE.

  Recruiting Phase 2 Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07145801

• Combining portal and hepatic vein embolization for liver cancer treatment

  This study is testing if combining two types of vein treatments can help more people with liver cancer have surgery and live longer.

  Recruiting Maastricht University · New Haven, Connecticut and 54 other locations · NCT06914648

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.